STOCK TITAN

Fortress Biotech (NASDAQ: FBIO) CFO receives 400,000 RSU award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jin David reported acquisition or exercise transactions in this Form 4 filing.

Fortress Biotech, Inc. Chief Financial Officer Jin David reported receiving an equity compensation grant of 400,000 restricted stock units, each representing one share of common stock. The units vest in four equal annual installments, with the first vesting on January 5, 2027, contingent on his continued service.

After this award, his reported holdings total 1,651,571 shares of common stock, including 1,230,000 shares underlying previously granted deferred restricted stock units. The transaction reflects a grant or award, not an open-market purchase.

Positive

  • None.

Negative

  • None.
Insider Jin David
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Common Stock, par value $0.001 400,000 $0.00 --
Holdings After Transaction: Common Stock, par value $0.001 — 1,651,571 shares (Direct, null)
Footnotes (1)
  1. Represents an award of 400,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in four equal annual installments, with the first installment vesting on January 5, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Vested restricted stock units will be settled in shares of the Issuer's common stock. Total holdings include 1,230,000 shares underlying previously granted deferred restricted stock units.
RSU grant size 400,000 restricted stock units Award to CFO Jin David reported on Form 4
Total holdings after transaction 1,651,571 shares Common stock held after RSU award
Deferred RSU underlying shares 1,230,000 shares Shares underlying previously granted deferred restricted stock units
Vesting schedule length 4 annual installments RSUs vest in four equal yearly tranches
First vesting date January 5, 2027 Initial vesting date for the RSU award
restricted stock units financial
"Represents an award of 400,000 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
deferred restricted stock units financial
"Total holdings include 1,230,000 shares underlying previously granted deferred restricted stock units."
Deferred restricted stock units are promises by a company to give employees or executives company shares at a future date, subject to conditions like continued employment or performance targets; the delivery and tax event are intentionally delayed. They matter to investors because they affect when new shares may be issued and how executives are motivated—like a paycheck held in escrow that vests over time, influencing potential share dilution and management behavior.
vesting financial
"The restricted stock units vest in four equal annual installments, with the first installment vesting on January 5, 2027."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jin David

(Last)(First)(Middle)
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301

(Street)
BAY HARBOR ISLANDS FLORIDA 33154

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [ FBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.00106/22/2026A400,000(1)A$01,651,571(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents an award of 400,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in four equal annual installments, with the first installment vesting on January 5, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Vested restricted stock units will be settled in shares of the Issuer's common stock.
2. Total holdings include 1,230,000 shares underlying previously granted deferred restricted stock units.
/s/ David Jin06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fortress Biotech (FBIO) report for CFO Jin David?

Fortress Biotech reported that CFO Jin David received a grant of 400,000 restricted stock units. Each unit represents one share of common stock as equity compensation, increasing his total reported holdings to 1,651,571 shares, including previously granted deferred restricted stock units.

How many restricted stock units did the Fortress Biotech (FBIO) CFO receive?

The CFO received an award of 400,000 restricted stock units from Fortress Biotech. Each restricted stock unit represents a contingent right to receive one share of common stock, subject to vesting conditions and his continued service with the company over several years.

What is the vesting schedule for Jin David’s Fortress Biotech (FBIO) RSU grant?

The 400,000 restricted stock units vest in four equal annual installments starting January 5, 2027. Each year one quarter of the units vests, provided Jin David continues serving the company through each applicable vesting date before settlement in common shares.

Did the Fortress Biotech (FBIO) CFO buy shares on the open market in this Form 4?

No, the filing shows a grant or award acquisition of restricted stock units to the CFO. The transaction code is “A,” indicating compensation-related equity, not an open-market purchase or sale of existing Fortress Biotech common stock by the insider.

What are Jin David’s total reported Fortress Biotech (FBIO) holdings after this grant?

After the award, Jin David’s total reported holdings are 1,651,571 shares of common stock. This figure includes 1,230,000 shares underlying previously granted deferred restricted stock units, in addition to the newly awarded 400,000 restricted stock units.

How are the Fortress Biotech (FBIO) restricted stock units for the CFO settled?

Vested restricted stock units for the CFO will be settled in shares of Fortress Biotech common stock. Each unit converts into one share once the applicable annual vesting condition is met and his continued service requirement through the vesting date is satisfied.